Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Autonomix Medical, Inc.AMIX · Entity 8309 | Director | August 11, 2025 | August 14, 2025 |
| Soliton, Inc.SOLY · Entity 132212 | Director · CSO and Vice Chairman | December 16, 2021 | December 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Autonomix Medical, Inc.
Report date August 11, 2025 · Filed August 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.00 · Expires 2033-09-08 | Direct | 0 |
Reported balance
After 2025-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-08-11 · Disposition to issuer · Disposed 3,750 · Balance 0 F1: Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation.
Soliton, Inc.
Report date December 16, 2021 · Filed December 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 1
1 source rowRow 1 · 2021-12-16 · Disposition to issuer · Disposed 263,440 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-12-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-16 · Disposition to issuer · Disposed 175,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. F2: Represents 175,000 shares of common stock held by M.D. Anderson Cancer Center ("MD Anderson") that were issued pursuant to a license agreement between Soliton, Inc. (the "Company") and MD Anderson. As the inventor of the intellectual property licensed from MD Anderson, Dr. Capelli is entitled to 50% of the proceeds (after the recoupment of any costs associated therewith) from the sale by MD Anderson of the shares issued to MD Anderson in connection with the license agreement. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-08 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-16 · Disposition to issuer · Disposed 725,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2029-02-04 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-16 · Disposition to issuer · Disposed 108,500 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2029-06-27 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-12-16 · Disposition to issuer · Disposed 35,150 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.71 · Expires 2030-02-04 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-12-16 · Disposition to issuer · Disposed 89,300 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.74 · Expires 2031-01-21 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-12-16 · Disposition to issuer · Disposed 113,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2023-10-19 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-12-16 · Disposition to issuer · Disposed 11,512 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2023-10-30 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-12-16 · Disposition to issuer · Disposed 8,634 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2023-11-15 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-12-16 · Disposition to issuer · Disposed 7,771 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest.
F2: Represents 175,000 shares of common stock held by M.D. Anderson Cancer Center ("MD Anderson") that were issued pursuant to a license agreement between Soliton, Inc. (the "Company") and MD Anderson. As the inventor of the intellectual property licensed from MD Anderson, Dr. Capelli is entitled to 50% of the proceeds (after the recoupment of any costs associated therewith) from the sale by MD Anderson of the shares issued to MD Anderson in connection with the license agreement.
F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option.
F4: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2025 Filed Aug 14, 2025 01:16 UTC | Autonomix Medical, Inc. AMIX · Entity 8309 | Disposition to issuerOption (Right to buy) · Derivative | 3,750 | Not disclosed Strike: $40.00 | Not disclosed |
DisclosureSEC source: 0001437749-25-026640 · rdgdoc.xml · derivative · entry 1 Capelli Christopher · CIK 0001768585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2033-09-08 F1 · derivative.exercise_price: Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation. F1 · shares: Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation. F1 · price: Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 17:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerWarrant (right to buy) · Derivative | 7,771 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001548187-21-000073 · wf-form4_163977881071003.xml · derivative · entry 10 Capelli Christopher · CIK 0001768585 · Director · CSO and Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,771 shares Expires 2023-11-15 F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 17:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerWarrant (right to buy) · Derivative | 8,634 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001548187-21-000073 · wf-form4_163977881071003.xml · derivative · entry 9 Capelli Christopher · CIK 0001768585 · Director · CSO and Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,634 shares Expires 2023-10-30 F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 17:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerWarrant (right to buy) · Derivative | 11,512 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001548187-21-000073 · wf-form4_163977881071003.xml · derivative · entry 8 Capelli Christopher · CIK 0001768585 · Director · CSO and Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,512 shares Expires 2023-10-19 F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 17:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerStock option (right to buy) · Derivative | 113,000 | Not disclosed Strike: $9.74 | Not disclosed |
DisclosureSEC source: 0001548187-21-000073 · wf-form4_163977881071003.xml · derivative · entry 7 Capelli Christopher · CIK 0001768585 · Director · CSO and Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,000 shares Expires 2031-01-21 F3 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 17:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerStock option (right to buy) · Derivative | 89,300 | Not disclosed Strike: $11.71 | Not disclosed |
DisclosureSEC source: 0001548187-21-000073 · wf-form4_163977881071003.xml · derivative · entry 6 Capelli Christopher · CIK 0001768585 · Director · CSO and Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,300 shares Expires 2030-02-04 F3 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 17:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerStock option (right to buy) · Derivative | 35,150 | Not disclosed Strike: $14.62 | Not disclosed |
DisclosureSEC source: 0001548187-21-000073 · wf-form4_163977881071003.xml · derivative · entry 5 Capelli Christopher · CIK 0001768585 · Director · CSO and Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,150 shares Expires 2029-06-27 F3 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 17:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerStock option (right to buy) · Derivative | 108,500 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001548187-21-000073 · wf-form4_163977881071003.xml · derivative · entry 4 Capelli Christopher · CIK 0001768585 · Director · CSO and Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,500 shares Expires 2029-02-04 F3 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 17:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerStock option (right to buy) · Derivative | 725,000 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001548187-21-000073 · wf-form4_163977881071003.xml · derivative · entry 3 Capelli Christopher · CIK 0001768585 · Director · CSO and Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 725,000 shares Expires 2028-06-08 F3 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 17:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerCommon Stock | 175,000 | $22.60 | $3,955,000.00 |
DisclosureSEC source: 0001548187-21-000073 · wf-form4_163977881071003.xml · nonDerivative · entry 2 Capelli Christopher · CIK 0001768585 · Director · CSO and Vice Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. F2 · ownership.nature: Represents 175,000 shares of common stock held by M.D. Anderson Cancer Center ("MD Anderson") that were issued pursuant to a license agreement between Soliton, Inc. (the "Company") and MD Anderson. As the inventor of the intellectual property licensed from MD Anderson, Dr. Capelli is entitled to 50% of the proceeds (after the recoupment of any costs associated therewith) from the sale by MD Anderson of the shares issued to MD Anderson in connection with the license agreement. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 17:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerCommon Stock | 263,440 | $22.60 | $5,953,744.00 |
DisclosureSEC source: 0001548187-21-000073 · wf-form4_163977881071003.xml · nonDerivative · entry 1 Capelli Christopher · CIK 0001768585 · Director · CSO and Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 17:21 UTC | Soliton, Inc. SOLY · Entity 132212 | GrantStock option (right to buy) · Derivative | 113,000 | Not disclosed Strike: $9.74 | Not disclosed |
DisclosureSEC source: 0001548187-21-000026 · wf-form4_161860806587722.xml · derivative · entry 1 Capelli Christopher · CIK 0001768585 · Director · CSO and Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,098,867 Underlying: Common Stock · 113,000 shares Expires 2031-01-21 F1 · date: The stock option was approved by the compensation committee of Soliton Inc.'s board of directors on January 21, 2021, subject to shareholder approval of the 2018 Stock Plan under which the option was granted. The shareholders of Soliton, Inc. approved the plan at the company's annual meeting on April 15, 2021. F3 · price: The stock options were issued in connection with the reporting person's employment with the Company. F2 · derivative.exercise_date: The stock options set forth in this table vest in four equal annual installments and are subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| February 04, 2020 Filed Feb 12, 2020 17:06 UTC | Soliton, Inc. SOLY · Entity 132212 | GrantStock option (right to buy) · Derivative | 89,300 | Not disclosed Strike: $11.71 | Not disclosed |
DisclosureSEC source: 0001548187-20-000016 · wf-form4_158154517817366.xml · derivative · entry 1 Capelli Christopher · CIK 0001768585 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 985,867 Underlying: Common Stock · 89,300 shares Expires 2030-02-04 F2 · price: The stock options were issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date and are subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 16:32 UTC | Soliton, Inc. SOLY · Entity 132212 | GrantStock option (right to buy) · Derivative | 35,150 | Not disclosed Strike: $14.62 | Not disclosed |
DisclosureSEC source: 0001437749-19-013233 · rdgdoc.xml · derivative · entry 1 Capelli Christopher · CIK 0001768585 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,160,007 Underlying: Common Stock · 35,150 shares Expires 2029-06-27 F2 · price: The stock options were issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date and are subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| June 27, 2019 Filed Feb 12, 2020 16:51 UTC Amendment | Soliton, Inc. SOLY · Entity 132212 | GrantStock option (right to buy) · Derivative | 35,150 | Not disclosed Strike: $14.62 | Not disclosed |
DisclosureSEC source: 0001548187-20-000011 · wf-form4a_158154429881244.xml · derivative · entry 1 Capelli Christopher · CIK 0001768585 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 896,567 Underlying: Common Stock · 35,150 shares Expires 2029-06-27 F2 · price: The stock options were issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date and are subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.